Clinical trials: Adrenal Cortical Cancer
Adrenocortical Carcinoma
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01528956
- Testing
- DNA methylation analysis, RNA analysis, gene expression analysis
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Adrenal Cortex Neoplasms, Adrenal Cortex Diseases
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
In adrenal tumors, the investigators will examine if there is any correlation between WIESS criteria, prognosis of the tumor, and the different labeling index of the following proliferation biomarkers: MCM3, MCM2, KI-67, P53…
- Trial name
- NCT02747355
- Volunteers
- 70 people
- Sponsor
- Bnai Zion Medical Center
Adrenocortical Carcinoma
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
- Trial name
- NCT04373265
- Testing
- Relacorilant, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Corcept Therapeutics
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Peritoneal Neoplasms, Retroperitoneal Neoplasms
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
There has been no successful treatment of diffuse peritoneal metastasis or carcinomatosis, in childhood tumors. Once this advanced stage of disease is evident, survival is measured in weeks.
- Conditions
- Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma
- Trial name
- NCT00436657
- Testing
- CHPP of Cisplatin, Abdominal Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Adrenocortical Carcinoma
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
This is a Phase II study of intravenous Bevacizumab in patients with pathologically confirmed nonresectable primary adrenocortical cancer (ACC). Patients must have received no prior therapy.
- Trial name
- NCT00469469
- Testing
- Bevacizumab
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer.
- Conditions
- Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
- Trial name
- NCT00304070
- Testing
- Cisplatin, Conventional Surgery, Doxorubicin Hydrochloride
- Where
- 91 sites in United States, Australia and 2 more
- Volunteers
- 78 people
- Sponsor
- Children's Oncology Group
Adrenal Tumor, Adrenal Mass
Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions
With our retrospective study the investigators show the limitations of the posterior retroperitoneal adrenalectomy by analyzing anatomical parameters.
- Conditions
- Adrenal Tumor, Adrenal Mass, Pheochromocytoma, Conn Adenoma
- Trial name
- NCT04071561
- Testing
- Posterior retroperitoneal adrenalectomy (PRA), Lateral transperitoneal adrenalectomy (LTA)
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- University of Basel
Adrenal Tumors, Adrenocortical Carcinoma
Adrenal Tumors - Pathogenesis and Therapy
The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates…
- Conditions
- Adrenal Tumors, Adrenocortical Carcinoma, Cushing Syndrome, Conn Syndrome
- Trial name
- NCT00669266
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Wuerzburg
Adrenocortical Carcinoma
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
The trial is a phase II trial in adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide results leading to the establishment of the effect of the included drugs.
- Trial name
- NCT00324012
- Testing
- cisplatin, taxotere
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Carcinoma Adrenal, Carcinoma, Adrenocortical Recurrent
Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort
This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated.
- Trial name
- NCT06279442
- Where
- 12 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- Latin American Cooperative Oncology Group
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma
Possible New Therapy for Advanced Cancer
IL-13-PE is a chemical similar to one made by the body that is connected to a toxin to specifically attack cancer cells. Researchers want to look at different doses of IL-13-PE to find one that may be safe and effective against…
- Trial name
- NCT01832974
- Testing
- IL-13-PE
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- INSYS Therapeutics Inc
Cancer, Neuroendocrine Tumors
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid…
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma
- Trial name
- NCT01262235
- Testing
- TKM-080301
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Arbutus Biopharma Corporation
Lung Cancer, Adrenal Insufficiency
Adrenal Function in Patients With Newly Diagnosed Lung Cancer
Patients with newly diagnosed lung cancer may have hypofunction of the adrenal cortex either from tumour metastasis or other mechanisms.
- Trial name
- NCT00364624
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Princess Margaret Hospital, Hong Kong
Adrenal Tumor, Primary Aldosteronism
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
This research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. The approach involves building prospective and retrospective patient registries, which will be…
- Conditions
- Adrenal Tumor, Primary Aldosteronism, Cushing Syndrome, Pheochromocytoma
- Trial name
- NCT06229405
- Where
- South Korea
- Volunteers
- 8,200 people
- Sponsor
- Seoul National University Hospital
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER